Evidence base — read this first
Part of a family of short synthetic peptides (2-4 amino acids) developed by Vladimir Khavinson's research group, each targeted at a specific tissue/organ. The evidence base for this entire peptide family shares the same limitation: it's concentrated almost entirely within this one research lineage (largely the same institute, often the same handful of authors), is mostly preclinical (rodent, cell-culture) or small Russian human pilot work, and hasn't been independently replicated by unaffiliated Western labs in a way this research pass could verify. None of these compounds is FDA or EMA approved for human use anywhere.
Benefits
Chonluten (Glu-Asp-Gly) is pitched as a lung/bronchial peptide (note: sharing the same reported sequence commonly cited for Bronchogen in secondary sources — this naming/sequence overlap wasn't independently resolved in this research pass and is worth clarifying with a supplier or primary source before publishing specific claims). No independently-verified specific study was confirmed.
How is this different from Bronchogen if both target the lungs?+
Worth confirming the exact distinction with the supplier — both are described as respiratory-system bioregulators from the same Khavinson research family, and the precise difference between the two isn't something I want to guess at rather than verify.
Looking for something specific, or placing a wholesale order? Send us a DM or email.